Methylcatechol (4-MC) is an agonist of various neurotrophic factors, which can upregulate
the expression of Heme oxygenase 1 (HO-1) protein by activating nuclear factor erythroid 2 …

Dysregulation of osteoclast‐osteoblast balance, resulting in abnormal bone remodeling, is
responsible for postmenopausal osteoporosis (PMOP) or other secondary forms of …

Osteoporosis, a systemic bone disease defined by decreased bone mass and deterioration
of bone microarchitecture, is becoming a global concern. Nodakenin (NK) is a …

Excessive RANKL signaling leads to superfluous osteoclast formation and bone resorption,
is widespread in the pathologic bone loss and destruction. Therefore, targeting RANKL or its …

Integrity of the skeleton is sustained through the balanced activities of osteoblasts and
osteoclasts in bone remodeling unit. The balance can be disrupted by excessive osteoclasts …

Ormeloxifene (Orm), a triphenylethylene compound, has been established as a selective
estrogen receptor modulator (SERM) that suppresses the ovariectomy-induced bone …

Osteoporosis, which typically affects postmenopausal women, is an osteolytic disease due
to over-activation of osteoclasts. However, current drugs targeting osteoclast inhibition face …

Background and purpose Osteoporosis is characterized by excessive bone resorption due
to enhanced osteoclast activation. Stimulation of nuclear factor of activated T cells 1 …

Receptor activator of nuclear factor-κB ligand (RANKL) has been found to induce
osteoclastogenesis and bone resorption. However, the underlying molecular mechanisms …

Osteoporosis is a bone disease that is exacerbated by aging and age-associated chronic
diseases such as cancer. Cancer-induced bone loss is usually treated with …